Merck KGaA has confirmed that it is in late-stage discussions with SpringWorks, valuing the deal at a price of around $47 per ...

Merck KGaA’s protracted pursuit of SpringWorks Therapeutics may be nearing its endgame. | Merck KGaA’s protracted pursuit of ...

The transaction, which sources say could be agreed upon as soon as Monday, would price SpringWorks at $47 per share, totaling ...

Germany's Merck KGaA said on Thursday it is in late-stage talks to acquire U.S.-based SpringWorks Therapeutics for about $3.5 ...

MilliporeSigma’s Curiosity Cube tours North America, Europe, and for the first time, Africa. In 2025, the mobile science lab ...

Scores of FDA employees are searching for an exit from an agency in turmoil, especially staffers tasked with reviewing drug ...

Nektar Therapeutics’s NKTR share price has surged by 6.77%, which has investors questioning if this is right time to sell.

Brent Jones; Chief Financial Officer, Executive Vice President; Avantor Inc Good morning. My name is Emily, and I'll be your conference operator today. At this time, I would like to welcome everyone ...

The report "Chromic Materials Market by Technology (Photochromism, Thermochromism, Electrochromism, Others), By Material, By Application (Smart ...

Q1 2025 Management View CEO Michael Stubblefield announced a leadership transition, stating that the Board of Directors has ...

Merck (MRK) stock rises as Summit Therapeutics (SMMT) posts latest survival data for lung cancer therapy ivonescimab ...

Merck projects $200 million in tariff costs, boosts U.S. manufacturing plans, and continues M&A efforts amid external pressures and shifting market dynamics.